AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Paolo A. Ascierto

Stock and Other Ownership Interests: PrimeVax

Consulting or Advisory Role: Bristol Myers Squibb, Roche/Genentech, Merck Sharp & Dohme, Novartis, Array BioPharma, Merck Serono, Pierre Fabre, Incyte, MedImmune, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Takis Biotech, Lunaphore Technologies, Seattle Genetics, ITeos Therapeutics, Medicenna, Bio-Al Health, ValoTx

Research Funding: Bristol Myers Squibb (Inst), Roche/Genentech (Inst), Array BioPharma (Inst), Sanofi (Inst), Pfizer (Inst)

Travel, Accommodations, Expenses: Merck Sharp & Dohme, Pfizer

Mario Mandalà

Honoraria: MSD Oncology, Novartis, Pierre Fabre, Sanofi/Aventis, Bristol Myers Squibb/Sanofi

Consulting or Advisory Role: Bristol Myers Squibb, MSD Oncology, Novartis, Pierre Fabre

Research Funding: Novartis (Inst)

Pier Francesso Ferrucci

Expert Testimony: Delcath Systems

Massimo Guidoboni

Consulting or Advisory Role: BMS, Novartis, Pierre Fabre

Speakers' Bureau: BMS, Novartis, Pierre Fabre

Research Funding: MSD

Piotr Rutkowski

Honoraria: Bristol Myers Squibb, MSD, Novartis, Roche, Pfizer, Pierre Fabre, Sanofi, Merck

Consulting or Advisory Role: Novartis, Blueprint Medicines, Bristol Myers Squibb, Pierre Fabre, MSD, Amgen

Speakers' Bureau: Pfizer, Novartis, Pierre Fabre

Research Funding: Novartis (Inst), Roche (Inst), Bristol Myers Squibb (Inst)

Travel, Accommodations, Expenses: Orphan Europe, Pierre Fabre

Virginia Ferraresi

Consulting or Advisory Role: Bristol Myers Squibb, Novartis

Speakers' Bureau: Bristol Myers Squibb, Novartis, Pierre Fabre, MSD Oncology

Ana Arance

Consulting or Advisory Role: BMS, Roche, Novartis, Pierre Fabre, MSD, Merck, Sanofi

Speakers' Bureau: Pierre Fabre, Novartis, MSD, BMS, Roche, Merck, Sanofi

Research Funding: Pierre Fabre (Inst), Novartis (Inst), Roche (Inst), BMS (Inst), MSD (Inst), Merck (Inst), Sanofi (Inst)

Travel, Accommodations, Expenses: BMS, MSD, Novartis, Pierre Fabre

Helen Gogas

Honoraria: Bristol Myers Squibb, MSD Oncology, Pierre Fabre, Sanofi/Regeneron

Consulting or Advisory Role: Bristol Myers Squibb, MSD Oncology, Amgen, Pierre Fabre, Sanofi/Regeneron

Research Funding: Bristol Myers Squibb (Inst), Roche (Inst), MSD Oncology (Inst), Amgen (Inst), Novartis (Inst), Iovance Biotherapeutics (Inst)

Travel, Accommodations, Expenses: Bristol Myers Squibb, MSD, Amgen, Pfizer

Erika Richtig

Honoraria: Amgen, Bayer, Bristol Myers Squibb, Merck Sharp Dohme, Merck, Novartis, Pierre Fabre, Roche, Sanofi

Consulting or Advisory Role: Amgen, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, Merck, Novartis, Pierre Fabre

Speakers' Bureau: Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Merck, Novartis, Pierre Fabre, Sanofi

Research Funding: Amgen (Inst), Bristol Myers Squibb (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), Pierre Fabre (Inst), Roche (Inst), CureVac (Inst), Incyte (Inst), Regeneron (Inst)

Travel, Accommodations, Expenses: Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Merck, Novartis, Pierre Fabre, Roche, Sanofi

Celeste Lebbè

Honoraria: Roche, Bristol Myers Squibb, Novartis, Amgen, MSD, Pierre Fabre, Pfizer, Incyte

Consulting or Advisory Role: Bristol Myers Squibb, MSD, Novartis, Amgen, Roche, Merck Serono, Sanofi, Pierre Fabre

Speakers' Bureau: Roche, Bristol Myers Squibb, Novartis, Amgen, MSD

Research Funding: Roche (Inst), Bristol Myers Squibb (Inst)

Travel, Accommodations, Expenses: Bristol Myers Squibb, MSD, Novartis, Sanofi, Pierre Fabre

Other Relationship: Avantis Medical Systems

Paola Queirolo

Consulting or Advisory Role: Roche/Genentech, Novartis, MSD, Bristol Myers Squibb, Pierre Fabre, Sanofi, Sun Pharma Advanced Research Company, Merck Serono

Travel, Accommodations, Expenses: MSD Oncology, Sanofi/Regeneron

Francesco Spagnolo

Honoraria: Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, Sanofi, Merck Serono, Sun Pharma

Consulting or Advisory Role: Novartis, MSD, Philogen, Sun Pharma, Pierre Fabre

Travel, Accommodations, Expenses: Bristol Myers Squibb

Marco Tucci

Honoraria: Novartis Italy, Bristol Myers Squibb/Celgene, Pierre Fabre

Consulting or Advisory Role: Novartis

Michele Del Vecchio

Consulting or Advisory Role: Novartis, Bristol Myers Squibb, Merck, Pierre Fabre

Maria Gonzales Cao

Honoraria: BMS Spain, MSD Oncology, Pierre Fabre, BeiGene Beijing, Sanofi

Speakers' Bureau: BMS Spain, MSD Oncology

Research Funding: Roche, AstraZeneca

Travel, Accommodations, Expenses: MSD Oncology

Alessandro Marco Minisini

Consulting or Advisory Role: Novartis, Pierre Fabre, MSD Oncology, Bristol Myers Squibb/Celgene, Sun Pharma, Sanofi/Aventis, Gilead Sciences, Merck Serono, Seattle Genetics, GlaxoSmithKline, AstraZeneca, PharmaMar

Sabino De Placido

Consulting or Advisory Role: Roche, Novartis, Pfizer, Lilly, Celgene, AstraZeneca/MedImmune, Seattle Genetics, Daiichi Sankyo/Astra Zeneca, MSD/AstraZeneca

Miguel F. Sanmamed

Consulting or Advisory Role: Numab, Bristol Myers Squibb/Medarex

Speakers' Bureau: MSD

Research Funding: Roche/Genentech (Inst)

Ignacio Melero

Honoraria: PharmaMar, Highlight Therapeutics

Consulting or Advisory Role: Bristol Myers Squibb, Bayer, Tusk Therapeutics, MSD, F-star, Genmab, EMD Serono, Lilly, AstraZeneca/MedImmune, Pieris Pharmaceuticals, Roche/Genentech, Numab, Noxxon Pharma, Servier, CRISPR therapeutics, Boston Pharmaceuticals, Monopteros Therapeutics, Moderna Therapeutics, CatalYm, Gossamer Bio, BioLineRx

Research Funding: Roche/Genentech, Bristol Myers Squibb, Alligator Bioscience, AstraZeneca, Bioncotech

Travel, Accommodations, Expenses: Bristol Myers Squibb, Roche/Genentech, Incyte, MSD

Giuseppe Palmieri

Consulting or Advisory Role: Pierre Fabre, Novartis

Antonio M. Grimaldi

Consulting or Advisory Role: Novartis, MSD Oncology, BMS Italy

Travel, Accommodations, Expenses: BMS Italy, Pierre Fabre, Novartis

Uncompensated Relationships: Novartis

Diana Giannarelli

Consulting or Advisory Role: MSD

Reinhard Dummer

Honoraria: Roche, Novartis, Bristol Myers Squibb, MSD, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, CatalYm, Second Genome, Regeneron, Alligator Bioscience, MaxiVax, touchIME, T3 Pharmaceuticals, Pfizer

Consulting or Advisory Role: Roche, Bristol Myers Squibb, MSD, Novartis, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, CatalYm, Second Genome, Alligator Bioscience, touchIME, MaxiVax, Regeneron, Pfizer, T3 Pharmaceuticals

Research Funding: Roche (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), MSD (Inst), Amgen (Inst)

Vanna Chiarion Sileni

Consulting or Advisory Role: Merck Serono, Bristol Myers Squibb, Novartis, Pierre Fabre

Speakers' Bureau: Bristol Myers Squibb, Novartis

Travel, Accommodations, Expenses: Bristol Myers Squibb, Pierre Fabre

No other potential conflicts of interest were reported.